Aprameya Engineering Limited — PPTs, 14-11-2025: Investor Presentation

Here's a concise summary of Aprameya Engineering's H1FY26 investor presentation:

**Business Performance:** Aprameya Engineering reported strong H1FY26 performance with revenue up 343% YoY to Rs 42.3 Cr and profit soaring 492% YoY to Rs 6.8 Cr (16% margin). Growth was primarily driven by turnkey projects, contributing 88% of revenue, including major Modular OT installations and advanced medical systems.

**Growth Drivers or Strategy:** The company targets 20-25% CAGR over the next three years, expanding into five new states and aiming for a Rs 300-350 Cr order book. A key strategy is scaling MedTech manufacturing, launching 5-6 new products by FY27, targeting Rs 50 Cr cumulative MedTech revenue by FY29, and focusing on import substitution.

**Recent Developments:** Aprameya recently entered medical device manufacturing through its subsidiary, Aprameya Medtech, launching 'HystroPress' for IVF and gynecology. They plan to introduce more specialist surgery products by FY26, initially via contract manufacturing. A Rs 16.4 Cr contract for Dialysis Machines is in their pending order book.

**Key Financial Metrics:** For H1FY26, revenue surged 343% YoY to Rs 42.3 Cr, with PAT jumping 492% YoY to Rs 6.8 Cr. EPS stood at Rs 3.6 (versus -Rs 1.0 last year), and EBITDA increased 1123% YoY to Rs 11.2 Cr, with a 26% margin.

**Management Commentary / Outlook:** Management highlighted strong execution, healthy revenue growth, and stable margins. They believe the next three years will be transformational, fueled by MedTech expansion, ambitious CAGR targets, and a robust order book and bid pipeline.